NCT05453214View on ClinicalTrials.gov

Mineralocorticoid Use in COVID-19 Patients

PHASE3CompletedINTERVENTIONAL
Enrollment

10

Participants

Timeline

Start Date

December 4, 2021

Primary Completion Date

March 3, 2022

Study Completion Date

June 20, 2022

Conditions
COVID-19ARDS
Interventions
DRUG

Fludrocortisone Acetate 0.1 MG

Fludrocortisone acetate 0.1 mg tablet / 12 hours; dose to be titrated according to response.

Trial Locations (1)

11591

Ain Shams University, Cairo

All Listed Sponsors
lead

Ain Shams University

OTHER

NCT05453214 - Mineralocorticoid Use in COVID-19 Patients | Biotech Hunter | Biotech Hunter